Studies of the neurochemical pathology of Alzheimer's disease and Parkinson's disease reveal a severe and specific loss of central nicotinic cholinergic receptors. We have investigated the functional significance of this finding for cognitive functioning by studying the effects of the centrally active nicotinic antagonist mecamylamine. Single oral doses of mecamylamine were administered to 12 healthy young males and 15 healthy elderly subjects in doses of 5, 10, and 20 mg in a placebo-controlled, double-blind study. In both groups, the 20-mg dose caused a significant increase in errors in the learning condition of the Repeated Acquisition Task, producing a slower acquisition curve. There was no effect of drug on the performance component (retrieval of previously learned information). However, elderly subjects showed en hanced sensitivity to mecamylamine,
with lO-mg dose producing significant impairment of learning not seen in the young normals. On a recognition memory task, there was an age-associated shift in response bias, with the elderly subjects becoming more liberal with increasing dose. Reaction-time measures suggested a dose-related slowing of reaction time on several tasks. Behavioral effects were minimal and physiologic effects were consistent with dose-related ganglionic blockade. These results indicate that acute blockade of nicotinic receptor function can produce measurable and significant cognitive impairment similar to some deficits seen in dementing illnesses, and that there is an age-related increase in sensitivity to nicotinic blockade. [Neuropsychopharmacology 10:93-107, 1994J gic mechanisms in normal cognitive functioning and disorders of memory function (Drachman and Leavitt 1974; Drachman 1977; Bartus et al. 1982 ; Whitehouse et al. 1982) . More recently, it has become apparent that patients suffering from AD and Parkinson's disease (PO) also have a marked reduction in cortical nicotinic cholinergic receptor binding compared to age-matched controls (Flynn and Mash 1986; Whitehouse et al. 1986 ; Perry et al. 1987; Giacobini 1990 ). However, the func tional signiflcance of this receptor loss for the cognitive disorder associated with these diseases is uncertain.
In animals, nicotine facilitates task acquisition and memory consolidation (Nelson and Goldstein 1972; Nordberg and Bergh 1985) , has been shown to improve delayed match-to-sample performance in monkeys (El rod et al. 1988) , and to reverse the effects of nucleus basalis lesions in the rat (Ksir and Benson 1983) . In hu mans, nicotine is reported to increase arousal and at-tention as well as to decrease reaction time, prevent de cline in efficiency over time, and improve the ability to withhold inappropriate responses (Wesnes and War burton, 1983) . In pilot studies (Newhouse et al. 1988b (Newhouse et al. , 1990 , we have shown that intravenous nicotine pro duces small but measurable improvements in several cognitive tasks in AD patients. Recently, Jones and col leagues (1992) have shown that acutely administered nicotine can improve attention and speed of informa tion processing in AD patients. These results suggest that central nicotinic cholinergic systems are important in human cognitive functioning and may be involved in the cognitive symptomatology of dementias such as AD and PD.
The use of a cholinergic antagonist has been suc cessful in evaluating the role of muscarinic systems in cognition using agents such as scopolamine (Sunder land et al. 1989 ) and atropine (Higgins et al. 1989) . The use of antagonists that have a high degree of specifIcity allows the identifIcation of cognitive operations affected by the interruption of agonist neurotransmission. Fur thermore, cognitive defIcits that follow drug adminis tration of antagonists can be compared to those of specifIc cognitive disorders such as AD to evaluate the clinical signifIcance of certain neurochemical defects. Although it would be overly simplistic to attempt to model the whole range of cognitive pathology of a com plex neurodegenerative disorder with a single an tagonist, the effects may indicate which cognitive do mains are influenced by lesions to the affected system (Weingartner et a1. 1987) .
The memory problems of early AD have been con ceptualized as difficulties in the storage of new infor mation. There is a gradient such that memory defIcits become more prominent as task difft culty increases: that is, as increasing organization and rehearsal of informa tion is needed for efficient storage and retrieval. This conceptualization has led to the hypothesis that as AD progresses, the internal representations of information become increasingly degraded or "noisy" such that it becomes harder to locate, store, and retrieve informa tion (Nebes et al. 1986; Grober et al. 1993 ). Related to this disorganization is that AD patients develop a liberal response bias on yes/no recognition and identification tasks (Corwin 1992; Snodgrass and Corwin 1988; Brandt et al. 1992) . This defect appears characteristic of AD and may be related to the well-known tendency of AD pa tients to make high numbers of intrusion errors (Fuld et al. 1982) . Overall, early defIcits in AD might be most parsimoniously described as difftculties with new learn ing due to problems in organization and consolidation of information coupled with a noisy semantic memory system. The degree to which these defIcits can be ascribed to particular neurochemical defects is unclear . However, these defIcits in cognitive operations may be secondary to loss of central cholinergic innervation NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO. 2 (Sunderland et al. 1989 ) and may be influenced by nico tinic receptor modulation. The goal of this investiga tion was to further examine the effects of acutely im pairing the nicotinic system on several of these cognitive processes.
These studies examined the effects of a temporary blockade of central nicotinic receptors by the drug mecamylamine on aspects of cognition. Mecamylamine is a centrally active noncompetitive antagonist of nico tine (and presumably acetylcholine) at C6 (ganglionic) type nicotinic receptors (Martin et al. 1989) . Through its action on presumed presynaptic nicotinic receptors, mecamylamine appears to antagonize anticholinester ase-induced release of acetylcholine in vitro (Nordberg et al. 1989 ). Mecamylamine has also been shown to pro duce an increase in cigarette smoking (Stolerman et al. 1973; Pomerleau et al. 1987) , to slow cortical EEG (Pick worth et al. 1988) , and to block the positive effects of nicotine on learning in monkeys (Elrod et al. 1988) . We have presented preliminary data suggesting that mecamylamine administered acutely to young healthy males produces impairment of several cognitive processes (Newhouse et al. 1992) . Here, we present ad ditional data from that experiment and report the results of additional studies in healthy elderly normal subjects of both sexes.
METHODS

Subjects
Twelve healthy young (mean age 23.9 ± 5. 0 years, range 19 to 36 years) male volunteers and 15 healthy elderly (mean age 62.7 ± 5.2 years; seven males and eight females) volunteers participated in this study. Subjects were determined by interview, physical exam, and laboratory tests to be free of signifIcant medical ill ness, psychiatric illness, or cognitive complaints. Elderly subjects were screened by a cognitive battery to ensure normal performance. The battery included the Mini Mental State exam and the Wechsler Memory Scale. Scores were required to be within the normal range. For the Mini Mental State exam, subjects had to have a score of 28 or greater. All subjects had at least a high school education and all were life-long non smokers.
Cognitive Measures
Pretesting training was done with each subject before each experiment to ensure stable asymptotic perfor mance and minimize practice effects. All testing was done blind to drug dosage.
Repeated Acquisition Test. This procedure (RAT) al lows the simultaneous measurement of a subject's abil-ity to retrieve previously acquired information as well as his/her ability to learn new information (Thompson 1973; Higgins et al. 1989) . In this procedure, during training, a subject learns a sequence of button pushes on a three-button panel, with reinforcement provided by a computer (training phase). On study days, the sub ject performs under two different conditions (retrieval and learning). In the retrieval condition, the correct re sponse sequence is always the same (the chain learned during training). In the learning condition, a new re sponse sequence must be learned each time the task is done. During testing, the subject alternates between the retrieval and learning conditions. This allows the assessment of state changes on both new learning and recall of old learning almost simultaneously. For these experiments, all subjects were taught a 10-button se quence for both the retrieval and learning conditions. Learning an d Recall. The Selective Reminding task was used to test acquisition and retention by recall. This standard test has been widely used in studies of cogni tive impairment and offers measures of storage into and retrieval from both short-term and long-term memory (Buschke and Fuld 1974) . The test list consisted of 14 words. Measures obtained include total recall, recall consistency (a measure of how long words were held in memory unreinforced), and recall failure, defIned as failing to recall a word after two successive reinforce ments.
Psychomotor Ability. A Choice Reaction Time (CRT) task was used to assess overall psychomotor ability, ac curacy, and speed of response. In this test, the num bers 0 to 9 appear sequentially on the screen, and the su bject responds each time by pushing the matching number on a key pad. The inter stimulus interval was 500 milliseconds. This test is a sensitive measure of atEffects of Mecamylamine on Cognition 95 tention, response time, and motor speed and is sensi tive to the effects of drugs that affect attention, such as anticholinergics and stimulants (Thorne et a1. 1985; Newhouse et al. 1989 Newhouse et al. , 1992 . A Manikin task was used as a test of spatial rotation. A human fIgure was presented in various orientations within a block or a circle, holding a smaller block or circle in one of its hands. The subject was asked to indicate which hand held the matching shape. Data obtained for both tasks included reaction time, number correct, and through put, a speed-accuracy product that is a measure of use ful work performed per unit time (Thorne et a1. 1985) .
Behavioral Measures
For observer ratings, the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham 1962) was used to mea sure psychopathologic behaviors. This scale appears to be sensitive to the behavioral changes induced by cholinergic drugs in both normals and AD patients (Sunderland et al. 1989) . A battery of Visual Analog Scales (VAS) consisting of a series of items such as "drowsiness" or "psychomotor agitation" were scored on 100 mm lines by the experimenter. Subjects com pleted the National Institutes of Mental Health Self Rating scale (Van Kammen and Murphy 1975) , VAS of self-report items rating aspects of mood, anxiety, alert ness and physical comfort, and a physical symptom checklist.
Physiologic Measures
Vital signs were taken while the subject was recumbent at 30-minute intervals and included systolic (SBP) and diastolic (DBP) blood pressure, pulse, respiratory rate, and oral temperature. In addition, a test of the or thostatic effect of the drug was made at 160 minutes after drug administration. This test consisted of mea suring pulse and BP before and after 5 minutes of standing.
Drugs
All drugs were administered double blind. The doses administered were 5, 10, and 20 mg of mecamylamine and placebo. These are doses both below and above that which produce a signifIcant increase in smoking be havior and a measurable drop in BP (Stolerman et a1. 1973; Pomerleau et al. 1987) .
Procedures
There were 4 drug days, each separated by at least 48 hours. The drug sequence was random except that the largest dose (20 mg) was not administered before at least one of the lower doses for safety reasons. Following an overnight fast, subjects were placed in bed in a recumbent position. The study began at 0730 hours with intravenous catheter insertion. At 0830 hours, baseline testing and evaluation were conducted. Drug was ad ministered at 0900 hours. Repeat cognitive testing was conducted at + 60 and + 120 minutes, and behavioral measures obtained at +60, + 120, and + 180 minutes. The cognitive battery was administered on a Zenith 286 microcomputer (with the exception of the Selective Reminding task). The computer, keyboard, and but ton box were placed on an over-bed table, and subjects remained in bed sitting up during the testing. Vital signs and blood samples were obtained at 3O-minute inter vals. Subjects were followed for 240 minutes after drug administration before being discharged. Some older subjects experienced prolonged orthostatic hypotension and were retained on the research ward until the fol lowing morning.
Data Analysis
The general approach was that of a completely repeated measures analysis of variance (ANOV A) or covariance (ANCOV A) (for variables that showed large day-to-day baseline differences) with dose, time, session, and trial as within-subjects repeated factors, age group as a between-subjects variable, and baseline as a covariate.
ModifIed F tests were used to adjust for correlated repeated measures (Vitaliano 1982) . SignifIcant differen tial dose effects were inferred from a signifIcant dose by-time interaction term. For the Buschke Selective Reminding Task, the components (total recall and con sistency) were analyzed with trial as an additional within-factor. The CRT and the Manikin tasks were ana lyzed by examining the mean reaction time and number and types of errors. For the Hi-Lo Imagery test, depen dent measures included estimates of discrimination and response bias calculated using the Two-High Threshold theory (Snodgrass and Corwin 1988) , per imagery con dition and trial.
Results
Cognitive measures are presented fIrst, followed by be havioral and physiologic measures and clinical obser vations. Results are presented flrst for young normals, followed by old normals and intergroup comparisons.
Results refer to the + 120-minute testing session unless otherwise indicated.
COGNITIVE MEASURES Repeated Acquisition
Young Normals. Examination of the mean number of errors during the learning condition showed a signifI- .077) for a main effect for dose in the quarter-life statis tic for the learning condition. The value tended to in crease with increasing dose, suggesting impairment of acquisition. Under the retrieval condition, there was no effect of drug (Fig. IB ). There were no drug-related changes in response speed or total time taken for ei ther condition.
Old Normals and Between-Group Comparison s. Anal ysis was restricted to the eight elderly subjects who were able to achieve the same baseline criterion performance as the young subjects. As with the young normals, mecamylamine produced a signifIcant (F[3,21] = 4.74, P = .02) dose-related increase in errors in the learning phase. However, in contrast to the young normals, both the 10-and 20-mg doses produced a similar number of errors, with cumulative errors being virtually identical for both doses by trial 20 (Fig. 2A) . This effect was responsible for a signifIcant (F[3,54] = 4.54, P = .017) dose-by-group interaction for total errors, indicating en hanced sensitivity in the old normal group. Evaluation of quarter-life during the learning phase again showed a trend (F[3,21] = 3.22, P < .97) for a dose-related in crease with both 10-and 20-mg doses showing higher values than the 5-mg dose and placebo. Between-group comparisons for quarter-life showed a signifIcant dose effect (F[3,54] = 6.32, P = .002) but no interaction with group, suggesting a similar magnitude of effect in both young and old.
Examination of speed was made by looking at re sponses per second during the learning phase. In ad dition to the large expected age effect, there was a signifIcant dose effect (F[3,54] = 4.37, P = .032). Post hoc comparisons showed that the 20-mg dose produced a signifIcantly (p < .04) slower response time in both Effects of Mecamylamine on Cognition 97 groups than did placebo, although the magnitude of the increase was greater in the older group (100% versus 17% increase).
The retrieval chain showed no signifIcant changes with drug in the old normal group (Fig. 2B ). There was no signifIcant age effect for total errors (p > .3), and no dose-related effects on quarter-life. Similarly there were no group effects on either parameter.
High-Low Imagery Task
Youn g Normals. Total PR (discrimination) showed a trend toward a dose-by-trial interaction (F[6.66] = 2.55, P = .066), with PR after the 20 mg dose smaller than the placebo value. Total response bias (BR) did not show a signifIcant dose effect, but there was a signifIcant (F[6,66] = 2.7, P < .03) dose-by-trial effect for high imagery words. There was a small decrease in BR that was evident at the second trial after the 5-mg dose only. analysis revealed that the elderly normals were im paired by both the 10 and the 20 mg doses in their abil ity to learn from trial 1 to 2, whereas the young nor mals showed a decline only on the 20-mg dose (Table  1) . By contrast, both groups showed proportionately similar declines in PR following the delay period. For high-imagery words, there was a strong trend (F[3,66] = 2.56, P = .06) for a dose-by-age interaction, with 
BEHAVIORAL MEASURES Young Normals
Subject. After ANCOV A was performed to adjust for varying baseline values, no signifIcant dose-by-time in teractions appeared in any self-rating, and there were no main effects. SignifIcantly, there were no changes in self-rated alertness, anxiety, or mood. The physical symptom checklist showed a trivial significant (p = .006) time effect, but no dose effect or interaction.
Observer. For the V AS battery, fatigue showed a trend (p < .06) towards a dose effect, but this effect appeared mainly due to the 5-mg dose, which had substantially lower ratings than the other two doses and placebo. For the BPRS, there were signifIcant dose-by-time in teractions for both the 18-(F[9,99] = 2.84, P < .009) and 24-item (p < .004) totals. However, the elevations were small and clinically insignificant (Table 2 ). For subscales, there were statistically signifIcant but clinically trivial dose-by-time interactions for the mania sub scale (p = .011) and the activation scale (p = .005). There was a signifIcant main effect (p = .008) for dose on the aner gia subscale, with the 20-mg dose producing slightly increased ratings.
Old Normals and Between-Group Comparisons
Subject. As with the young normals, no ratings showed significant dose-related changes. The physical symptom checklist showed no dose-related increases in total score.
Observer. No items from the V AS showed a significant dose-related increase. Similar to the young normals, the BPRS showed a signifIcant dose-by-time interaction for the 18-item total (F[6,84] Mecamylamine produced a dose-related decline in SBP, DBP, and oral temperature and produced a dose-related increase in pulse and pupil diameter (Table 3) . Exami nation of the orthostatic BP test showed that there was signifIcant dose-related reductions in DBP (F[3,30] = 4.79, P = .014) and pulse rise (F = 2.94, P = .049).
Comparing the groups, there was a signifIcant dose-by-age-by-time interaction for SBP (F[27,594] = 1.93, P = .008) and a signifIcant dose-by-age interac tion for DBP (F[3,66] = 3.41, P = .02). Similarly, there were signifIcant dose-by-age interactions for the or thostatic BP test on DBP (F[3,69] = 2.65, P = .05) and pulse (F = 7.67, P = .0002). Older individuals showed a greater effect of mecamylamine on cardiovascular parameters and were signifIcantly impaired in their abil ity to maintain BP and pulse when challenged with or thostatic challenge (Fig. 5) .
Clinical Observations
As the behavioral ratings indicated, the observable effects of the drug were very mild. Subjects did occa sionally complain of feeling "fuzzy" or slowed on the 10-or 20-mg dose, although not all were accurate in dis tinguishing their doses. Several subjects on the 20-mg dose noted persistent mild cognitive effects for some hours after the completion of the protocol. For some of the older subjects, signifIcant orthostatic hypoten sion (asymptomatic unless standing) persisted for up to 8 hours following the 20-mg dose. For those subjects, it was necessary to maintain them at bed rest until BP recovered.
DISCUSSION
In this investigation, the nicotinic antagonist mecamyla mine produced cognitive impairment on several tasks. These effects included impairment of acquisition on the RAT task, impaired recall on the Selective Reminding task, slowing of reaction time, and impairment of PR and liberalization of BR on the Hi -Low Imagery task.
Furthermore, there was evidence that elderly normals were proportionately more sensitive to the effects of mecamylamine. The lack of clinically signifIcant be havioral changes and physical side-effects suggests that the cognitive effects were secondary to speciftc block ade of nicotinic receptors and not due to nonspecifIc effects on arousal or overall well-being. Here, we re view the effects on task performance and explore the possible mechanisms involved. Second, we discuss the signifIcance of these data for the role of nicotinic recep tors in the neurobiology of cognitive operations. Finally, we address the implications of these results for models of disease-related cognitive dysfunction and therapeutic drug development.
On the RAT task, mecamylamine produced a dose related impairment in the acquisition of new informa tion, although it did not impair the retrieval of old information. At this level of analysis, we cannot be cer tain which part(s) of the acquisition process is affected.
However, mecamylamine may interfere with attend ing properly to reinforcement from the computer; sec-
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ond, the recall failure seen suggests that the ability to move information into long-term store may be reduced (i.e., that the encoding is "noisy") or that the decay of the memory trace is accelerated. Retrieval of the old chain was not substantially affected, suggesting that re trieval of well-learned information may not be medi ated by the same mechanisms or that it is less vulnera ble to disruption. In rats, mecamylamine has been shown to disrupt acquisition of new spatial locations more than retrieval of previously learned locations (Decker and Majchrzak 1992; Riekkinen et al. 1990) . than the CRT, which only involves number matching.
Behavioral effects of mecamylamine in this study were minimal. Subjects blind to dosage did not report any consistent mood or anxiety changes, and they did not report any consistent physical side effects. SignifI-cantly, they did not show any dose-related increase in drowsiness or sleepiness. Small elevations seen on the BPRS and a few subscales were not clinically meaning ful and were generally much smaller than effects seen with cognitively impairing doses of muscarinic antag onists (Sunderland et al. 1989; Newhouse et al. 1988a) .
No age group differences emerged. Physiologic effects were consistent with dose related ganglionic blockade but were more marked in the older subjects. They showed less ability to compen sate for the hypotensive effects by increasing their cardiac rate and cardiac output, as evidenced by the in ability of those subjects to raise pulse and sustain BP under orthostatic challenge. Older subjects showed a decline in temperature, an effect not seen in the young normals. These results suggest that aging produces in creased sensitivity to ganglionic blockade, which may be a reflection of fewer peripheral nicotinic receptors or impaired compensatory mechanisms or both. The relationship between peripheral cardiovascular sensi tivity and cognitive sensitivity to nicotinic antagonism remains to be further explored.
The role(s) of central nicotinic systems in cognitive operations remains the subject of considerable interest, particularly with the developing understanding of the anatomic distribution of central nicotinic receptors (Schwartz 1986; Saji et al. 1992 ) and their molecular bi ology (Luetje et al. 1990; Heinemann et al. 1991) . Nico tinic receptors appear to be involved in modulating many transmitter systems but especially those involv ing ACh (Rowell and Winkler 1984) and dopamine (Grady et a1. 1992) . Although there appears to be a population of postsynaptic nicotinic receptors, many receptors may lie in a presynaptic position and modu late the release of neurotransmitters (Schwartz et al. 1984; Grady et al. 1992 ). For example, there appears to be a signifIcant population of nicotinic receptors in the CAl region of the hippocampus (Freund et al. 1990 ) that may interact with gamma-aminobutyric acid recep tors. The effects of mecamylamine on inhibiting the transfer of information from short-term or working memory into long-term store seen in this study could be mediated in part through effects on the hippocampus (Squire and Zola-Morgan 1991) .
There appears to be a tight relationship between nicotinic cholinergic receptors and dopamine systems, as evidenced by animal learning studies. The effects of mecamylamine on radial maze learning can be reversed by the dopamine D2 agonist L Y 171555 (Levin et a1. 1989) . Impaired learning following lesions of the medial cholinergic pathway are similarly improved by the same agonist, which abolishes the mecamylamine effect (McGurk et a1. 1992) . Dopamine antagonists also have been shown to block the facilitatory effects of nicotine on avoidance learning (Brioni and Arneric 1993) . More study will be necessary to establish whether mecamyla-NEUROPSYCHOPHARMACOLOGY 1994-VOL. 10, NO.2 mine, and by inference, nicotinic systems mediate effects on learning through dopamine systems in humans.
The interaction of nicotinic receptors with central muscarinic cholinergic receptors may be substantial, as nicotine has been shown to release ACh, probably onto postsynaptic muscarinic receptors (Rowell and Winkler 1984; Clarke et al. 1987) . Amnesia after mecamylamine administration has been correlated with decreases in regional brain ACh synthesis (Elrod and Buccafusco 1991) . Coadministration of nicotinic and muscarinic an tagonists produces supraadditive dehcits on a variety of memory tasks in animals (Levin et al. 1989; Riekki nen et al. 1990) . A study of combined administration of mecamylamine and scopolamine in humans (Gitel man and Prohovnik 1992) showed a greater impairment of memory scores on the Selective Reminding Task than that seen with scopolamine alone.
It is possible that some of the effects of mecamyla mine may be mediated through nonnicotinic receptors. Mecamylamine is a noncompetitive antagonist that probably has its mode of action through direct block ade of the nicotinic receptor ion channel (Takayama et al. 1989 ). It appears that mecamylamine also interacts with other receptors that utilize ion channels, such as the N-methyl-D-aspartate (NMDA) receptor (Snell and Johnson, 1989; O'Dell and Christiansen 1988) , which may be important in hippocampal function. It is possi ble that some effects on memory mechanisms could be mediated through actions on these receptors, although the doses of mecamylamine necessary to impair learn ing do not appear to block NMDA receptors (Levin 1992) . The actions of NMDA receptor antagonists on animal learning do not match those of mecamylamine (Decker and Majchrzak 1992) . Furthermore, in humans, the doses of the noncompetitive NMDA antagonist ketamine necessary to produce mild cognitive impair ment produce profound behavioral changes similar to dissociative states and schizophrenia (Krystal et al. 1994) .
These hndings have implications for the under standing of the nature of the role of nicotinic systems in the cognitive dehcits seen in AD and PD. These results suggest that the loss of central nicotinic recep tors seen in normal aging (Court et al. 1992 ) and in AD and PD (Aubert et al. 1992 ) has functional conse quences. The dehcits produced by mecamylamine resemble, in several respects, those seen in AD and to a lesser extent PD. Dehcits in short-and long-term mem ory, impaired attention, liberal bias and decreases in reaction time are hallmarks of the dementing picture seen in these disorders. The age-related nature of some of the hndings suggest that the decline in nicotinic receptors with age produces increased vulnerability to the effects of nicotinic blockade. It is possible that the young subjects would have shown more cognitive im- Finally, the results suggest that nicotinic modula tion may be of benefit for the alleviation or improve ments of cognitive impairments in various dementing disorders that show a loss of nicotinic receptors. Modu lation of these presynaptic receptors, either through di rect stimulation or allosteric modulation, may increase the activity or gain of other phasic neurotransmitter sys tems that may be directly responsible for the cognitive operation (Levin 1992 ) and may be a more effective method than direct stimulation of the postsynaptic, no nnicotinic receptor. Nicotine is unlikely to be an ideal candidate for this task, due to its low therapeutic in dex, but other, more selective agonists or other allosteric modulators may be useful in this regard (Lena and Changeux 1993) .
